AI
KALV

Atom Investors’s KalVista Pharmaceuticals KALV Stock Holding History

Atom Investors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-245,993
Closed -$4.95M – 928
2026
Q1 		$4.95M Sell
245,993
-30,120
-11% -$485K 0.35% 81
2025
Q4 		$4.46M Buy
+276,113
New +$3.66M 0.35% 89
2025
Q3 		– Sell
-16,312
Closed -$184K – 722
2025
Q2 		$184K Buy
+16,312
New +$199K 0.02% 521
2024
Q3 		– Sell
-19,901
Closed -$234K – 535
2024
Q2 		$234K Sell
19,901
-45,104
-69% -$526K 0.02% 406
2024
Q1 		$771K Sell
65,005
-4,839
-7% -$64.5K 0.1% 256
2023
Q4 		$856K Buy
69,844
+4,558
+7% +$41.5K 0.15% 204
2023
Q3 		$629K Buy
65,286
+31,727
+95% +$324K 0.14% 195
2023
Q2 		$302K Buy
33,559
+10,975
+49% +$101K 0.11% 188
2023
Q1 		$178K Buy
+22,584
New +$169K 0.1% 216

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Atom Investors's KALV Position: Q2 2026 in Review

Atom Investors sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 245,993 shares — an estimated $4.95M sold.

Atom Investors first reported a position in KALV in Q1 2023 and held it in 9 quarters. The position peaked at $4.95M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Atom Investors reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Atom Investors sold 245,993 KalVista Pharmaceuticals shares in Q2 2026, an estimated $4.95M.
  • Atom Investors first reported a position in KalVista Pharmaceuticals in Q1 2023 and held it in 9 quarters.
  • Atom Investors's KalVista Pharmaceuticals position peaked at $4.95M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.